Their initial timeline was Q2 2020. We are in Q3 2021 and we learn that they may submit: - pieces (not everything) - “as early as” - but but but only got GUIDANCE from the FDA. Basically reading the FDA website could also be called guidance.
This is a new low for Cytodyn : it’s the 20h disappointment over a major promise in only 18 months.
Why does rejection of the lasted portion of the CYDY BLA submission yield any confidence, particularly in light of recent colossal failures? Seems like more of the same. Oh, I get it…NP is “ failing forward”. We were fed the same BS narrative on the original submission, what proof is there that anything has changed?